Articles tagged "Immunosuppression"

2019 American Transplant Congress
Combined Antithymocyte Globulin (ATG) and Rituximab (RTX) Induction in African American (AA) Kidney Transplant Recipients
S. J. Patel, S. Kuten, C. Pham, R. Knight, M. Hobeika, D. Nguyen, E. Graviss, S. Yi, T. Eagar, A. Gaber
Methodist Hospital, Houston, TX
*Purpose: We have previously shown that despite the use of T cell-depleting antibody induction, AA kidney transplant recipients (KTR) remain at high risk of rejection…
2019 American Transplant Congress
Transplantation Alone Induces Myeloid-Derived Suppressor Cells Which Can Suppress T Cell Responses
Y. Lee, T. Zhang, J. S. Bromberg, J. R. Scalea
University of Maryland, Baltimore, MD
*Purpose: Myeloid-derived suppressor cells (MDSC) are a naturally occurring, heterogeneous population of highly immunosuppressive CD11b+GR-1+ cells that expand in response to inflammatory conditions. MDSCs develop…
2019 American Transplant Congress
A Cost Saving Quality Improvement Project in Solid Organ Transplant Population Following Tacrolimus Switch from Prograf® to Adoport® Immunosuppression – A Single Centre Experience
L. Mulreid, M. Vincent, L. Laycock, A. Summers, S. Bhutani
Manchester Royal Infirmary, Manchester, United Kingdom
*Purpose: Tacrolimus is widely used immunosuppressive drugs in transplantation. The use of generic medications is cost saving and economically advantageous for the National Health Services…
2019 American Transplant Congress
Time to First Therapeutic Tacrolimus Trough in Kidney Transplant Recipients: A Comparison of a Weight Based versus a Non-Weight Based Dosing Strategy
M. Chunduru, K. Schnelle, S. Zhao, L. Wei, R. Daloul
Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Reaching a therapeutic tacrolimus (TAC) trough early post-kidney transplant is important in minimizing the risk of acute rejection. The aim of this study was…
2019 American Transplant Congress
A Multicenter Study Of mTOR Inhibitor Use In Intestine And Multivisceral Transplantation
M. C. Segovia¹, A. Mavis¹, J. Boike², Y. Patel¹, T. Schiano³, S. Jafri⁴
¹Duke, Durham, NC, ²NWU, Chicago, IL, ³Mt Sinai, NY, NY, ⁴Henry Ford, Detroit, MI
*Purpose: Review the frequency, indications and outcomes of the use of mTOR inhibitors (mTOR) after intestine (IT) and multivisceral transplantation (MVT) at multiple centers in…
2019 American Transplant Congress
Early Outcomes Comparing Two Steroid-Avoidance Protocols in Pediatric Renal Transplantation
D. Puliyanda¹, H. Pizzo¹, N. Rodig², M. Somers²
¹Cedars-Sinai Med Ctr, Los Angeles, CA, ²Pediatric Nephrology, Boston Childrens Hospital, Boston, MA
*Purpose: Steroid-avoidance in pediatric kidney transplants (txs) was found effective and safe with daclizumab induction. Upon daclizumab’s discontinuation, lymphocyte-depleting agents became used in this setting,…
2019 American Transplant Congress
Four-Year Follow Up of Kidney Transplantation Using Alemtuzumab Induction and Belatacept/Sirolimus Maintenance Therapy
A. Kirk¹, H. Xu¹, A. Ghali², A. Mehta², A. Guasch²
¹Surgery, Duke University, Durham, NC, ²Transplant Center, Emory University, Atlanta, GA
*Purpose: Kidney transplantation remains limited by the chronic toxicities associated with calcineurin inhibitors (CNIs) and steroids. The objective of this clinical trial was to determine…
2019 American Transplant Congress
Impact of Once-Daily Tacrolimus on Trough Concentration Variability in Stable Adolescent and Young Adult Renal Transplant Recipients
M. Moss, J. Goebel, A. Lofton, E. Steinberg, M. Bock
Children's Hospital Colorado, Aurora, CO
*Purpose: High tacrolimus concentration variability (Vtac), likely influenced by medication non-adherence, is a risk factor for graft dysfunction and loss among renal transplant recipients (RTRs),…
2019 American Transplant Congress
Lack of Response to Tocilizumab in Kidney Transplants with Chronic Antibody-Mediated Rejection
D. Kumar¹, F. Safavi¹, R. Sandhu¹, P. Halloran², I. Yakubu¹, M. Levy¹, I. Moinuddin¹, P. Kimball¹, L. Kamal¹, A. King¹, H. Massey¹, G. Gupta¹
¹Virginia Commonwealth University, Richmond, VA, ²Alberta Transplant Genomics Applied Centre, Edmonton, AB, Canada
*Purpose: Chronic antibody mediated rejection (cAbMR) is a major cause of long-term kidney transplant (KT) loss. Traditional therapies for cAbMR have unclear efficacy with significant…
2019 American Transplant Congress
Early Tacrolimus Trough Attainment in De Novo Kidney Transplant Recipients Treated with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac)
K. Budde¹, S. Bunnapradist², S. J. Patel³, D. R. Stevens³, U. Meier-Kriesche³, B. Suwelack⁴
¹Charité University Medicine Berlin, Berlin, Germany, ²UCLA Medical Center, Los Angeles, CA, ³Veloxis Pharmaceuticals Inc., Cary, NC, ⁴University Hospital of Münster, Münster, Germany
*Purpose: Early achievement of therapeutic tacrolimus concentrations has been associated with reduced rates of acute rejection. A prospective, randomized, controlled study demonstrated safe and efficacious…